Oncology Institute, Inc. (TOI) has disclosed a new risk, in the Accounting & Financial Operations category.
The Oncology Institute, Inc. faces a significant business risk if it must record further goodwill impairment charges. The company’s financials have already been impacted by a $16,867 impairment due to a diminished fair value of its reporting unit, influenced by declining stock prices and adverse macroeconomic and industry conditions. Future assessments, driven by persistent or worsening factors, could mandate additional impairments, potentially affecting the entire balance of remaining goodwill and jeopardizing the company’s adherence to financial covenants within its Facility Agreement. Such developments could substantially deteriorate Oncology Institute’s financial health and operating results.
Overall, Wall Street has a Moderate Buy consensus rating on TOI stock based on 1 Buy.
To learn more about Oncology Institute, Inc.’s risk factors, click here.
